JP2011518857A5 - - Google Patents

Download PDF

Info

Publication number
JP2011518857A5
JP2011518857A5 JP2011506688A JP2011506688A JP2011518857A5 JP 2011518857 A5 JP2011518857 A5 JP 2011518857A5 JP 2011506688 A JP2011506688 A JP 2011506688A JP 2011506688 A JP2011506688 A JP 2011506688A JP 2011518857 A5 JP2011518857 A5 JP 2011518857A5
Authority
JP
Japan
Prior art keywords
amino acid
seq
acid sequence
functional fragment
sequence shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2011506688A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011518857A (ja
JP5771140B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2009/055129 external-priority patent/WO2009133103A1/en
Publication of JP2011518857A publication Critical patent/JP2011518857A/ja
Publication of JP2011518857A5 publication Critical patent/JP2011518857A5/ja
Application granted granted Critical
Publication of JP5771140B2 publication Critical patent/JP5771140B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2011506688A 2008-04-29 2009-04-28 治療用のgm−csfおよびil−17阻害剤 Active JP5771140B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12588008P 2008-04-29 2008-04-29
US61/125,880 2008-04-29
PCT/EP2009/055129 WO2009133103A1 (en) 2008-04-29 2009-04-28 Inhibitors of gm-csf and il-17 for therapy

Publications (3)

Publication Number Publication Date
JP2011518857A JP2011518857A (ja) 2011-06-30
JP2011518857A5 true JP2011518857A5 (enExample) 2012-05-24
JP5771140B2 JP5771140B2 (ja) 2015-08-26

Family

ID=40810025

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011506688A Active JP5771140B2 (ja) 2008-04-29 2009-04-28 治療用のgm−csfおよびil−17阻害剤

Country Status (16)

Country Link
US (1) US9353180B2 (enExample)
EP (1) EP2279001B1 (enExample)
JP (1) JP5771140B2 (enExample)
KR (2) KR20160117643A (enExample)
CN (2) CN102014958A (enExample)
AU (1) AU2009242088B2 (enExample)
BR (1) BRPI0911469A8 (enExample)
CA (1) CA2717987C (enExample)
EA (1) EA024654B1 (enExample)
ES (1) ES2557494T3 (enExample)
IL (1) IL209028A (enExample)
MX (1) MX2010011309A (enExample)
NZ (1) NZ587865A (enExample)
UA (1) UA102097C2 (enExample)
WO (1) WO2009133103A1 (enExample)
ZA (1) ZA201006353B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120164101A1 (en) * 2009-04-30 2012-06-28 Jacques Galipeau Gm-csf and interleukin-21 conjugates and uses thereof in the modulation of immune response and treatment of cancer
US20140044731A1 (en) * 2011-01-04 2014-02-13 Robert Nussenblatt Methods of treating age-related macular degeneration
BR112013033944A2 (pt) 2011-07-06 2017-12-19 Morphosys Ag combinação sinérgica
US9901079B2 (en) 2011-08-18 2018-02-27 New York University Inhibition of oncogenic kras-induced GM-CSF production and function
WO2013090989A1 (en) 2011-12-22 2013-06-27 Csl Limited Method of treating inflammatory bowel disease
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
AR093297A1 (es) 2012-10-31 2015-05-27 Amgen Res Munich Gmbh Formulacion liquida que comprende un compuesto neutralizante de gm-csf
RU2714919C2 (ru) 2013-08-30 2020-02-21 Такеда Гмбх Антитела, нейтрализующие gm-csf, для применения в лечении ревматоидного артрита или в качестве анальгетиков
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
CN111690063A (zh) * 2020-05-25 2020-09-22 北京大学 一种抗gm-csf纳米抗体及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309636B1 (en) * 1995-09-14 2001-10-30 Cancer Research Institute Of Contra Costa Recombinant peptides derived from the Mc3 anti-BA46 antibody, methods of use thereof, and methods of humanizing antibody peptides
NZ539271A (en) * 2002-10-30 2008-12-24 Genentech Inc Inhibition of the production of proinflammatory cytokine interleukin-17 (IL-17) by T cells, using an antagonist of interleukin-23 (IL-23)
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
EP1828250A2 (en) * 2004-12-16 2007-09-05 Genentech, Inc. Methods for treating autoimmune disorders
MX2007012569A (es) * 2005-04-18 2007-12-06 Micromet Ag Neutralizadores de anticuerpos del factor estimulante de la colonia de macrofagos-granulocitos humanos.
KR101395515B1 (ko) * 2006-02-08 2014-05-14 모르포테크, 인크. 항원성 gm-csf 펩티드 및 gm-csf에 대한 항체

Similar Documents

Publication Publication Date Title
CN104774266B (zh) 白介素-13结合蛋白
JP5836130B2 (ja) ヒトil−13に結合特異性を有する抗体分子
RU2007138341A (ru) Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека
TW201031421A (en) IL-1 binding proteins
JP2007514419A5 (enExample)
JP2023505492A5 (enExample)
JP2009539349A5 (enExample)
KR101820699B1 (ko) 항-vegf/dll4 이원 가변 도메인 면역글로불린 및 이의 용도
CN108473568A (zh) 对TNF-α、IL-17A和IL-17F具有特异性的多特异性抗体分子
JP2008542321A5 (enExample)
HK1128495B (en) Interleukin -13 binding proteins
HK1128495A (en) Interleukin -13 binding proteins